GCA
ABMD

Gideon Capital Advisors’s Abiomed Inc ABMD Stock Holding History

Gideon Capital Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,565
Closed -$447K – 470
2019
Q1 		$447K Buy
+1,565
New +$520K 0.16% 196
2018
Q3 		– Sell
-1,139
Closed -$466K – 521
2018
Q2 		$466K Buy
+1,139
New +$413K 0.23% 158
2018
Q1 		– Sell
-1,222
Closed -$229K – 492
2017
Q4 		$229K Buy
+1,222
New +$228K 0.2% 235

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Gideon Capital Advisors's ABMD Position: Q2 2019 in Review

Gideon Capital Advisors sold out of Abiomed Inc (ABMD) in Q2 2019, closing a stake of 1,565 shares — an estimated $447K sold.

Gideon Capital Advisors first reported a position in ABMD in Q4 2017 and held it in 3 quarters. The position peaked at $466K in Q2 2018. 483 funds tracked by Wall St. Rank hold ABMD as of Q2 2019.

  • Gideon Capital Advisors reported no remaining Abiomed Inc position as of Q2 2019 after selling out during the quarter.
  • Gideon Capital Advisors sold 1,565 Abiomed Inc shares in Q2 2019, an estimated $447K.
  • Gideon Capital Advisors first reported a position in Abiomed Inc in Q4 2017 and held it in 3 quarters.
  • Gideon Capital Advisors's Abiomed Inc position peaked at $466K in Q2 2018.
  • 483 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2019.

Based on Gideon Capital Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.